StockMarketWire.com - Immunodiagnostics group Oncimmune Holdings said it was confident of being able to generate 'material profitable revenues', thanks to several business developments.

The company had earlier this month reported positive data from an early lung cancer detection, or ECLS, test study.

It had also inked distribution agreements over the past 12 months across 19 countries, with combined minimum sales commitments of £34.6m over the next five years.

'The positive ECLS study top line data, the potential for the forthcoming commercial cancer evaluation in Scotland, the depth of the company's distributor pipeline and the current ongoing discussions across the breadth of it business, give the directors confidence in the strength of Oncimmune's platform, the number of addressable opportunities, and the company's potential to generate material profitable revenues,' the company said.


At 9:03am: [LON:ONC] Oncimmune Holdings Plc share price was +0.5p at 86.5p



Story provided by StockMarketWire.com